Tue, August 2, 2011
Mon, August 1, 2011
Sun, July 31, 2011
Fri, July 29, 2011
Thu, July 28, 2011
Wed, July 27, 2011
[ Wed, Jul 27th 2011 ] - Market Wire
00 AM EDT
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011
Wed, July 20, 2011
[ Wed, Jul 20th 2011 ] - Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ] - Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ] - Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
Sun, July 10, 2011
Sat, July 9, 2011
Fri, July 8, 2011

Kendall Law Group Investigates Allos Therapeutics, Inc.


//health-fitness.news-articles.net/content/2011/ .. w-group-investigates-allos-therapeutics-inc.html
Published in Health and Fitness on Wednesday, July 20th 2011 at 7:46 GMT by Market Wire   Print publication without navigation


DALLAS--([ BUSINESS WIRE ])--[ Kendall Law Group ], led by former federal judge Joe Kendall, is investigating Allos Therapeutics, Inc. (NASDAQ: ALTH) for shareholders in connection with the proposed acquisition by AMAG Pharmaceuticals, Inc. The national securities firma™s investigation seeks to determine whether Allos Therapeutics and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an Allos Therapeutics shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [ investor@kendalllawgroup.com ].

On July 20, 2011, the companies announced the definitive merger agreement under which Allos Therapeutics would be acquired by AMAG Pharmaceuticals, in a transaction valued at approximately $260 million. Under the terms of the agreement, Allos Therapeutics stockholders will receive a fixed ratio of 0.1282 shares of AMAG common stock for each share of Allos Therapeutics/ALTH common stock held. The deal values Allos Therapeutics stock at $2.44 a share using AMAG Pharmaceuticals' Tuesday closing price of $19.07. According to Thompson/First Call, analysts have set a price target as high as $8.00 per share for Allos Therapeuticsa™ stock. The firma™s investigation seeks to determine whether Allos Therapeutics and its Board undertook a fair process in negotiating the deal.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.


Publication Contributing Sources